Majid Mohammed Mahmood*
, Zenab Ghanim Younus Al-Ameen, Hassan Dede Meshay, Ghid Nahd Abdulmuhssen, Yasameen M Bani Wais
1-Unit of Zoonotic Diseases, College of Veterinary Medicine, University of Baghdad, Iraq
2-College of Pharmacy, University of Baghdad, Iraq
3-FIBMS (Fellow of Iraqi Board of Medical Specialties), Hematopathologist, Hematology Lab, Iraqi Ministry of Health
4-Chairman of Scientific Committee of Alkarkh General Hospital. Ministry of Health of Iraq
5-Hematopathologist, Private sector. Baghdad, Iraq
*Corresponding author: dr.Majid.Mahmood80@covm.uobaghdad.edu.iq
Received: May 19, 2021 / Revised: June 21, 2021/ Accepted: June 25, 2021
How to cite this article:
Mahmood, M. M., Al-Ameen, Z. G. Y., Meshay, H. D., Abdulmuhssen, G. N., Wais, Y. M. B. (2021). Convalescent plasma (CP) is one major key factor to cure COVID-19 as a life-saving medicine: A comprehensive overview. Science Archives, Vol. 2 (2), 144-149. http://dx.doi.org/10.47587/SA.2021.2214
Copyright
This is an open-access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.
References
Ahn, J. Y., Sohn, Y., Lee, S. H., Cho, Y., Hyun, J. H., Baek, Y. J. and Yeom, J.-S. (2020). Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. Journal of Korean Medical Science, 35(14), e149.
Beeson, P., Chesney, G.and McFarlan, A. (1944). Hepatitis following Injection of Mumps Convalescent Plasma. I. Use of Plasma in the Mumps Epidemic. Lancet, 814-815.
Bloch, E. M., Shoham, S., Casadevall, A., Sachais, B. S., Shaz, B., Winters, J. L. andHenderson, J. P. (2020). Deployment of convalescent plasma for the prevention and treatment of COVID-19. The Journal of Clinical Investigation, 130(6), 2757-2765.
Brainard, J., Pond, K., Hooper, L., Edmunds, K., and Hunter, P. (2016). Presence and persistence of Ebola or Marburg virus in patients and survivors: a rapid systematic review. PLoS Neglected Tropical Diseases, 10(2), 1-17.
Burnouf, T. andRadosevich, M. (2003). Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Medical Journal, 9(4), 309.
Burnouf, T.and Seghatchian, J. (2014). Ebola virus convalescent blood products: where we are now and where we may need to go. Transfusion and Apheresis Science, 51(2), 120-125.
Casadevall, A., and Pirofski, L.-A. (2020). The convalescent sera option for containing COVID-19. The Journal of Clinical Investigation, 130(4), 1545-1548.
Chen, L., Xiong, J., Bao, L., and Shi, Y. (2020). Convalescent plasma as a potential therapy for COVID-19. The Lancet Infectious Diseases, 20(4)(4), 398-400.
Cheng, Y., Wong, R., Soo, Y., Wong, W., Lee, C., Ng, M. andCheng, G. (2005). Use of convalescent plasma therapy in SARS patients in Hong Kong. European Journal of Clinical Microbiology and Infectious Diseases, 24(1), 44-46.
Cheng, Y., Wong, R., Soo, Y. O. Y., Wong, W. S., Lee, C. K., Ng, M. H. L. andCheng, G. (2005). Use of convalescent plasma therapy in SARS patients in Hong Kong. European Journal of Clinical Microbiology and Infectious Diseases, 24(1), 44-46.
Cross, R. W., Mire, C. E., Feldmann, H. and Geisbert, T. W. (2018). Post-exposure treatments for Ebola and Marburg virus infections. Nature Reviews Drug Discovery, 17(6), 413-434.
Cunningham, A. C., Goh, H. P. and Koh, D. (2020). Treatment of COVID-19: old tricks for new challenges. Critical Care, 24, 91.
Dowty, B., Carlisle, D., Laseter, J. L. and Gonzalez, F. M. (1975). Gas chromatographic mass spectrometric computer analysis of volatile components in blood plasma from hemodialysis patients. Biomedical Mass Spectrometry, 2(3), 142-147.
Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J. and Hu, Y. (2020a). Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences, 117(17), 9490-9496.
Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J. and Hu, Y. (2020b). The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study. medRxiv.
Frame, J. D., Verbrugge, G. P., Gill, R. and Pinneo, L. (1984). The use of Lassa fever convalescent plasma in Nigeria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 78(3), 319-324.
Gowda, A. and McNichols, R. (2002). Apparatus for access to interstitial fluid, blood, or blood plasma components., United States Patent. Patent Nunmber: US 6,459,917 B1.
Hamilton, P. B. and Archibald, R. M. (1944). Dialysis Cell for Rapid Quantitative Analytical Determination of Diffusible Components in Blood Plasma. Industrial and Engineering Chemistry Analytical Edition, 16(2), 136-137.
Hawley, W., McFarlan, A. and Steigman, A. (1944). Hepatitis following Injection of Mumps Convalescent Plasma. III. Clinical and Laboratory Study. Lancet, 818-821.
Hoffbrand, A. V., Higgs, D. R., Keeling, D. M. and Mehta, A. B. (2016). Postgraduate Haematology: John Wiley & Sons.
Hung, I. F., To, K. K., Lee, C.-K., Lee, K.-L., Chan, K., Yan, W.-W. and Lai, K.-Y. (2011). Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clinical Infectious Diseases, 52(4), 447-456.
Jahrling, P. B., Frame, J. D., Rhoderick, J. B. and Monson, M. H. (1985). Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. Transactions of the Royal Society of Tropical Medicine and Hygiene, 79(3), 380-384.
Keith, P., Day, M., Perkins, L., Moyer, L., Hewitt, K. and Wells, A. (2020). A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19. Critical Care, 24, 128.
Lesne, E., Brodin, P. and Saint-Girons, F. (1919). Plasma therapy in influenza. Presse Med, 27, 181-182.
Linder, M. (2016). Ceruloplasmin and other copper binding components of blood plasma and their functions: an update. Metallomics, 8(9), 887-905.
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J. and Huang, A.-L. (2020). Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nature Medicine, 26, 1200–1204.
Luke, T. C., Kilbane, E. M., Jackson, J. L. and Hoffman, S. L. (2006). Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Annals of Internal Medicine, 145(8), 599-609.
MacLennan, S. andBarbara, J. A. (2006). Risks and side effects of therapy with plasma and plasma fractions. Best Practice and Research Clinical Haematology, 19(1), 169-189.
Mair-Jenkins, J., Saavedra-Campos, M., Baillie, J. K., Cleary, P., Khaw, F.-M., Lim, W. S. and Nguyen-Van-Tam, J. S. (2015). The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. The Journal of Infectious Diseases, 211(1), 80-90.
Marano, G., Vaglio, S., Pupella, S., Facco, G., Catalano, L., Liumbruno, G. M. and Grazzini, G. (2016). Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfusion, 14(2), 152.
McFarlan, A. and Chesney, G. (1944). Hepatitis following Injection of Mumps Convalescent Plasma. II. Epidemiology of the Hepatitis. Lancet, 816-871.
Milkins, C., Berryman, J., Cantwell, C., Elliott, C., Haggas, R., Jones, J. and Win, N. (2013). British Committee for Standards in Haematology (BCSH), Guidelines for pre‐transfusion compatibility procedures in blood transfusion laboratories. Transfusion Medicine, 23(1), 3-35.
Natesan, M., Jensen, S. M., Keasey, S. L., Kamata, T., Kuehne, A. I., Stonier, S. W. andUlrich, R. G. (2016). Human survivors of disease outbreaks caused by Ebola or Marburg virus exhibit cross-reactive and long-lived antibody responses. Clinical and Vaccine Immunology, 23(8), 717-724.
NPHEC. (2020). Nature Public Health Emergency Collection (NPHEC). Chloroquine and hydroxychloroquine increase risk of death in COVID-19. Reactions Weekly, 1806(1), 1.
Ota, M. (2020). Will we see protection or reinfection in COVID-19? Nature Reviews Immunology, 20, 351.
Peiris, J. S. M., Chu, C.-M., Cheng, V. C.-C., Chan, K., Hung, I., Poon, L. L. and Chan, C. (2003). Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. The Lancet, 361(9371), 1767-1772.
Rajendran, K., Narayanasamy, K., Rangarajan, J., Rathinam, J., Natarajan, M., & Ramachandran, A. (2020). Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. Journal of Medical Virology, 92(9), 1475-1483.
Rambar, A. C. (1946). Mumps: use of convalescent serum in the treatment and prophylaxis of orchitis. American Journal of Diseases of Children, 71(1), 1-13.
Roback, J. D. and Guarner, J. (2020). Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA, 323(16), 1561-1562.
Rojas, M., Rodríguez, Y., Monsalve, D. M., Acosta-Ampudia, Y., Camacho, B., Gallo, J. E. and Manrique, R. (2020). Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmunity Reviews, 19(7), 102554.
Rubin, R. (2020). Testing an old therapy against a new disease: convalescent plasma for COVID-19. JAMA, 323(21), 2114-2117.
Salin, R. W., Curtis, A. C. and Wheeler, A. (1957). The treatment of pityriasis rosea with convalescent plasma, gamma globulin, and pooled plasma. AMA Archives of Dermatology, 76(5), 659-662.
Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J. and Xing, L. (2020). Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA, 323(16), 1582-1589.
Soo, Y. O., Cheng, Y., Wong, R., Hui, D. S., Lee, C. K., Tsang, K. K. andSung, J. J. (2004). Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clinical Microbiology and Infection, 10(7), 676-678.
Syal, K. (2020). COVID-19: herd immunity and convalescent plasma transfer therapy. Journal of Medical Virology, 92(9), 1380-1382.
Tanne, J. H. (2020). Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ, 368, m1256.
Tiberghien, P., de Lamballerie, X., Morel, P., Gallian, P., Lacombe, K. and Yazdanpanah, Y. (2020). Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? VoxSanguinis, 115(6), 488-494.
US-FDA. (2020a). FDA Issues Emergency Use Authorization for Convalescent Plasma as Potential Promising COVID–19 Treatment, Another Achievement in Administration’s Fight Against Pandemic. Available at: https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment. Accessed 15 June 2021.
US-FDA. (2020b). Recommendations for Investigational COVID-19 Convalescent Plasma. Available at: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma. Accessed 15 June 2021.
US-FDA. (2020c). Investigational COVID-19 Convalescent Plasma. Guidance for Industry. Available at: https://www.fda.gov/media/136798/download. Accessed 15 June 2021.
US-FDA. (2020d). Hydroxychloroquine-online.com. Available at: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hydroxychloroquine-onlinecom-607727-07092020. Accessed 15 June 2021.
Van Griensven, J., De Weiggheleire, A., Delamou, A., Smith, P. G., Edwards, T., Vandekerckhove, P. and Lazaygues, C. (2016). The use of Ebola convalescent plasma to treat Ebola virus disease in resource-constrained settings: a perspective from the field. Clinical Infectious Diseases, 62(1), 69-74.
Van Griensven, J., Edwards, T., de Lamballerie, X., Semple, M. G., Gallian, P., Baize, S. and Antierens, A. (2016). Evaluation of convalescent plasma for Ebola virus disease in Guinea. New England Journal of Medicine, 374(1), 33-42.
WHO. (1977). Marburg and Ebola virus infections: a guide for their diagnosis, management and control. Available at: https://apps.who.int/iris/bitstream/handle/10665/37138/WHO_OFFSET_36.pdf?sequence=1. Accessed 15June 2021.
WHO. (2014). Use of Convalescent Whole Blood or Plasma Collected from Patients Recovered from Ebola Virus Disease for Transfusion, as an Empirical Treatment during Outbreaks. Version 1.0. Available at: https://apps.who.int/iris/bitstream/handle/10665/135591/WHO_HIS_SDS_2014.8_eng.pdf. Accessed 15June 2021.
WHO. (2020). World Health Organisation (WHO). “Solidarity” clinical trial for COVID-19 treatments. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments. Accessed 15June 2021.
Wong, H. K., Lee, C. K., Hung, I. F., Leung, J. N., Hong, J., Yuen, K. Y. and Lin, C. K. (2010). Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection. Transfusion, 50(9), 1967-1971.
Wong, V., Dai, D., Wu, A. and Sung, J. (2003). Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Medical Journal, 9(3), 199-201.
Worldmeter. (2021). COVID-19 Coronavirus Pandemic. Available at: https://www.worldometers.info/coronavirus/. Accessed 17 June 2021.
Xu, X., Sun, J., Nie, S., Li, H., Kong, Y., Liang, M. and Ma, T. (2020). Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. Nature Medicine, 26, 1193–1195.
Ye, M., Fu, D., Ren, Y., Wang, F., Wang, D., Zhang, F. and Lv, T. (2020). Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. Journal of Medical Virology, 92(10), 1890-1901.
Yeh, K.-M., Chiueh, T.-S., Siu, L., Lin, J.-C., Chan, P. K., Peng, M.-Y. and Perng, C.-L. (2005). Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. Journal of Antimicrobial Chemotherapy, 56(5), 919-922.
Zeng, Q.-L., Yu, Z.-J., Gou, J.-J., Li, G.-M., Ma, S.-H., Zhang, G.-F. andZhang, M.-M. (2020). Effect of convalescent plasma therapy on viral shedding and survival in COVID-19 patients. The Journal of Infectious Diseases, 1(1), 38–43.
Zhai, P., Ding, Y., Wu, X., Long, J., Zhong, Y. and Li, Y. (2020). The epidemiology, diagnosis and treatment of COVID-19. International Journal of Antimicrobial Agents, 55(5), 105955.
Zhang, B., Liu, S., Tan, T., Huang, W., Dong, Y., Chen, L. andZhang, X. (2020). Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest, 158(1), e9-e13.
Zhang, L., Pang, R., Xue, X., Bao, J., Ye, S., Dai, Y., Yi, Y. (2020). Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19. Aging (Albany NY), 12(8), 6536.
Zhao, Q. and He, Y. (2020). Challenges of convalescent plasma therapy on COVID-19. Journal of Clinical Virology, 127, 104358.
Zhou, B., Zhong, N. and Guan, Y. (2007). Treatment with convalescent plasma for influenza A (H5N1) infection. New England Journal of Medicine, 357(14), 1450-1451.
Zhou, M., Zhang, X. andQu, J. (2020). Coronavirus disease 2019 (COVID-19): a clinical update. Frontiers of Medicine, 14, 126–135.
License Article Metadata
This work is licensed under a Creative Commons Attribution 4.0 International License.
